FRANKREICH

Kaufman & Broad SA: IMPLEMENTATION OF THE SHARE BUY-BACK PROGRAM

Retrieved on: 
Vendredi, juillet 19, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Further to Kaufman & Broad's SA announcement of the implementation of its share buy-back program [1] pursuant to the 15th resolution of the Shareholders' General Meeting of May 6th, 2024, Kaufman & Broad SA renewed, dated of July 16th , 2024, and for a new twelve-months period, the irrevocable share buy-back agreement entrusted to an independent investment services provider.
  • This agreement provides for the buy-back of Kaufman & Broad SA shares up to a maximum number of shares representing 8.041% of Kaufman & Broad SA's share capital subject to market conditions.
  • The description of the share buy-back program authorized by the Shareholders' Meeting of May 6th, 2024, was published on the same day, and is available on the Company's website ( www.kaufmanbroad.fr . )

Sartorius Stedim Biotech SA: Information on Document Availability

Retrieved on: 
Vendredi, juillet 19, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • The report on the first half 2024 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:
    It contains the following information:
    Consolidated financial statements for the period ended June 30, 2024
    Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry.
  • The shares of
    Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris.
  • Sartorius
    Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies.

Sartorius Stedim Biotech SA: Sartorius Stedim Biotech adjusts its guidance for fiscal year 2024 and presents results for H1 2024

Retrieved on: 
Jeudi, juillet 18, 2024

Sartorius Stedim Biotech offers a wide range of innovative technologies for the manufacture of biopharmaceuticals such as monoclonal antibodies, vaccines, and cell and gene therapeutics.

Key Points: 
  • Sartorius Stedim Biotech offers a wide range of innovative technologies for the manufacture of biopharmaceuticals such as monoclonal antibodies, vaccines, and cell and gene therapeutics.
  • As of June 30, 2024, Sartorius Stedim Biotech employed 10,382 people worldwide, after 11,135 in the prior-year period (December 31, 2023: 10,662 people).
  • Sartorius Stedim Biotech shall not assume any liability for the correctness of this translation.
  • Furthermore, Sartorius Stedim Biotech reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided.

FOCUS ENTERTAINMENT: 2024/25 first-quarter revenue of €34.2m, driven by a solid back-catalogue up sharply by 17%

Retrieved on: 
Jeudi, juillet 18, 2024

This quarter saw the release of SnowRunner season 13, Insurgency: Sandstorm update 1.16 “Operation Crisis”, as well as the launch of the DLC of Warhammer 40,000: Boltgun “Forges of Corruption”.

Key Points: 
  • This quarter saw the release of SnowRunner season 13, Insurgency: Sandstorm update 1.16 “Operation Crisis”, as well as the launch of the DLC of Warhammer 40,000: Boltgun “Forges of Corruption”.
  • excluding the Scripteam business consolidated as from 14 December, revenue amounted to €32.8m.
  • International sales, which included nearly 50% in North America, accounted for 95% of the Group’s revenue for the quarter.
  • The game is published by FOCUS Entertainment Publishing and will be launched in PC, Xbox Series and PlayStation 5 versions.

Zone-Éco and Waga Energy commission a renewable natural gas production unit in Cowansville, Quebec

Retrieved on: 
Mardi, juillet 16, 2024

Zone-Éco and Waga Energy commission a renewable natural gas production unit in Cowansville, Quebec

Key Points: 
  • Zone-Éco and Waga Energy commission a renewable natural gas production unit in Cowansville, Quebec
    Dissemination of a French Regulatory News, transmitted by EQS Group.
  • Zone-Éco and Waga Energy commission a renewable natural gas production unit in Cowansville, Quebec
    (Cowansville (Quebec, Canada), July 16, 2024) Zone-Éco and Waga Energy commissioned a renewable natural gas (RNG) production unit at a landfill site in Cowansville, Quebec (Canada).
  • On July 3, 2024, Zone-Éco, a landfill, composting and recycling service provider, and Waga Energy, a global expert in the production of Renewable Natural Gas (RNG) from landfills, commissioned a RNG production unit at a landfill site in Cowansville (Quebec, Canada).
  • Thanks to the WAGABOX® technology, developed and patented by Waga Energy, the biogas spontaneously emitted by landfilled waste at the site is upgraded in the form of RNG, a renewable substitute for fossil-based natural gas.

EQS-News: Abivax Provides Operational and Key Program Update

Retrieved on: 
Lundi, juillet 15, 2024

With Ms. Grégoire joining the Board of Directors, Carol Brosgart, MD will be resigning from the Abivax Board.

Key Points: 
  • With Ms. Grégoire joining the Board of Directors, Carol Brosgart, MD will be resigning from the Abivax Board.
  • Mr. de Garidel said “On behalf of the Abivax Board of Directors, I would like to warmly welcome Sylvie           to the team.
  • These adjustments to the obefazimod CD clinical program are not expected to have an impact on the overall program budget and projected supplemental New Drug Application (sNDA) submission timeline.
  • Selection of the first follow-on drug candidate is expected before the end of 2024 to further strengthen the Abivax pipeline.

Kaufman & Broad SA: NEW SYNDICATED LOAN AGREEMENT FOR €200M OVER 5 YEARS

Retrieved on: 
Lundi, juillet 15, 2024

Kaufman & Broad announces that on 10 July 2024, it signed a €200M syndicated loan agreement with an initial maturity of 5 years.

Key Points: 
  • Kaufman & Broad announces that on 10 July 2024, it signed a €200M syndicated loan agreement with an initial maturity of 5 years.
  • This loan replaces the existing ‘RCF 2019’ syndicated loan agreement for an amount of €250M, maturing in January 2025.
  • This facility includes a positive incentive mechanism based on several CSR indicators, demonstrating the company's environmental commitment.
  • Crédit Agricole Corporate and Investment Bank acted as mandated Arranger and advised Kaufman & Broad in association with Banque Postale on CSR aspects as CSR Coordinator.

EQS-News: Andera Partners’ portfolio company Amolyt Pharma completes acquisition by AstraZeneca

Retrieved on: 
Lundi, juillet 15, 2024

AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for up to $1.05 billion.

Key Points: 
  • AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for up to $1.05 billion.
  • Paris (France), Lyon (France), and Cambridge, MA (USA), July 12th, 2024 – Andera Partners, a leading European private equity player, announced today that its portfolio company Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, closed its previously announced acquisition by the global pharmaceutical company AstraZeneca.
  • This programme, together with Amolyt’s talented team, expertise, and earlier pipeline, will enable Alexion’s expansion into rare endocrinology.
  • Under the terms of the definitive agreement, AstraZeneca has acquired all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05 billion, on a cash and debt free basis.

EQS-News: Affluent Medical announces the availability of a prospectus for the admission to trading of 6,190,831 shares issued as part of a capital increase without preferential subscription rights in favour of

Retrieved on: 
Lundi, juillet 15, 2024

(4) It should be noted that:

Key Points: 
  • (4) It should be noted that:
    the holdings of Kreos Capital and Ginko Invest previously included in this category are no longer included.
  • The Prospectus is available on the AMF website (www.amf-france.org) and on the Company's website (https://www.affluentmedical.com).
  • Copies of the Prospectus are available free of charge at the Company’s registered office at 320 avenue Archimède - Les pléiades III Bâtiment B - 13100 Aix-en-Provence.
  • The occurrence of some or all of these risks may have an adverse impact on the Group’s business, financial position, results or ability to achieve its targets.